【摘要】 目的　探讨异种胰岛细胞肝内移植临床应用的可行性 ,了解猪胰岛细胞植入糖尿病病人肝内以后是否可控制病人血糖 ,了解移植后可能发生的并发症。方法　培养 7～ 10d的新生猪胰岛细胞 ,经肝动脉植入 4例Ⅰ型糖尿病病人肝内 ;其中 2例植入 4× 10 6个胰岛细胞 ,2例植入 8× 10 6个胰岛细胞。移植后病人使用的抗排斥方案为 :术后当天 ,使用甲泼尼龙 5 0 0mg,第 2天将甲泼尼龙降至 5 0mg ,3d后服用泼尼松并逐步减量至 10mg ,维持该剂量 1个月 ;环孢素 8mg/kg ,每日 2次 ,使用 12个月 ;霉酚酸酯 2g/d ,使用 2 5d。测量移植前后外源性胰岛素用量、葡萄糖耐量试验、血糖以及糖化血红蛋白。观察病人一般情况及肝、肾功能变化。结果　由于使用甲泼尼龙的原因 ,移植后病人的外源性胰岛素用量一度上升至 6 0mg。随着甲泼尼龙用量的减少 ,外源性胰岛素的用量逐渐减少 ,较移植前减量约 32 %～ 5 8%。胰岛素减量幅度与植入胰岛细胞数量相关。移植以后糖尿病病人糖化血红蛋白减少 ,血糖较移植前明显稳定 ,肝肾功能维持正常 ,病人体重增加 ,一般情况改善。移植异种胰岛细胞以后未发现肝功能和外周血CD4阳性淋巴细胞和CD8阳性淋巴细胞异常。结论　经肝动脉移植猪胰岛细胞治疗Ⅰ型糖尿病是安全、有效的治疗方法。所使用的抗更多还原

【Abstract】 Objective Liver is an important site to host transplanted islets, and implanting of islets by hepatic artery is simpler than by portal vein. Our study evaluated efficiency of the method and possible complication in a clinical setting. Methods From October 1998 to June 2000, 4 type I diabetic patients received 4×10 6 (2 cases) and 8×10 6 (2 cases) of NPI through hepatic artery. Before Tx, all cases had the history with ketosis and acidosis. Exogenous insulin doses used for these cases were 25-48 units and their GHb was 9%-11%. After Tx, the NPI recipients were treated with immunosuppressants including ciclosporin 8 mg/kg for 12 months, cellcept 2 g/d for 25 days, and methylprednisolone 500 mg at 1st day, then reduced to 50 mg for 3 days until to 10 mg for 1 month. Liver function and CD4/CD8 of the recipients were measured before and after Tx. Results After Tx, the dose of exogenous insulin was increased to 60 mg due to methylprednisolone treatment. When methylprednisolone dose was decreased, the requirement for insulin was reduced to 32%-58% of the dose used before Tx. The reduction of required insulin for NPI recipients was proportional to the number of implanted NPI. In addition, GHb was also reduced to normal level (4%-6%) 3 months after Tx. No significant alterations of liver function and CD4 and CD8 in blood were observed after Tx. Conclusion Transarterial introhepatic xenotransplantation of NPI is an efficient and safe therapeutic method for type I diabetes. Combination of ciclosporin, cellcept, and methylprednisolone is an effective immunosuppressive strategy for NPI xenograft transplantation.更多还原